Advances in gene therapy and artificial intelligence are accelerating research into ways of slowing aspects of biological ageing, with a number of experimental approaches now moving from animal studies toward human clinical trials.
Life Biosciences, a biotechnology company founded by Harvard researcher David Sinclair, has begun an early human clinical trial of a therapy based on partial cellular reprogramming.
The approach uses genes associated with so-called Yamanaka factors, which researchers hope can reset aspects of cellular ageing without completely converting mature cells into stem cells.
In the trial, the experimental therapy is being investigated for patients with glaucoma and optic nerve damage, with the treatment delivered to the eye. Initial safety findings are expected toward the end of 2026 or in early 2027, according to the report.
Sinclair has previously suggested that humans could eventually achieve substantially longer lifespans, although such predictions remain speculative and are not established outcomes of current clinical research.
Another prominent Harvard geneticist, George Church, has also discussed the concept of “longevity escape velocity,” a hypothetical point at which advances in medicine could add more than a year of healthy life expectancy for each year that passes.
Artificial intelligence is also being used in longevity research to help identify potential gene-delivery methods and develop improved versions of proteins involved in cellular reprogramming.
Results from animal studies have generated considerable interest. Some researchers have reported substantial lifespan and health improvements in ageing mice using combinations of experimental approaches, including senolytic immunotherapy and personalised stem-cell treatments.
Other studies have investigated drugs such as rapamycin and experimental compounds, with some reporting lifespan increases of 30% or more in mice.
Researchers have also found evidence that certain medications developed for weight management may influence biological markers associated with ageing and extend lifespan in animal models. However, findings in mice cannot automatically be translated into equivalent effects in humans.
Scientists stress that human immortality remains far beyond current medical capabilities. Accidents, emerging diseases and fundamental biological limitations remain major barriers, including age-related changes and DNA damage in cells that have limited capacity to divide.
The movement of cellular-reprogramming therapies into human trials nevertheless represents an important step in longevity research. Whether these approaches can safely produce meaningful increases in human healthspan or lifespan will depend on the results of clinical trials and longer-term research.